iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN) (OTCPK: ITHUF), which owns, operates and partners with regulated cannabis operations across the United States, announces that, due to the challenges related to COVID-19 and the expected reconstitution of the board of directors of the Company contemplated in connection with the previously announced recapitalization transaction (the “Recapitalization Transaction”), the Company’s management determined that it is in the best interest of shareholders to postpone the Company’s 2020 annual general meeting (“AGM”). The Company has been granted an extension (of up to six months with an outside date of June 30, 2021) by the BC Registrar of Companies, which will allow the Company sufficient time to prepare the required information circular and communicate effectively with shareholders on material matters. The Company will continue to monitor the COVID-19 situation and, as the Recapitalization Transaction progresses, the Company will set a date for its next AGM and will file a notice of meeting and record date on the Company’s website and under the Company’s SEDAR profile at www.sedar.com.
For further details on the Court’s approval for the Recapitalization Transaction, see the Company’s news release dated October 6, 2020, a copy of which is available under the Company’s SEDAR profile at www.sedar.com.
iAnthus owns and operates licensed cannabis cultivation, processing and dispensary facilities throughout the United States. For more information, visit www.iAnthus.com.
COVID-19 Risk Factor
The Company may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19. An outbreak of infectious disease, a pandemic, or a similar public health threat, such as the recent outbreak of COVID-19, or a fear of any of the foregoing could adversely impact the Company by causing operating, manufacturing, supply chain, and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Company may be affected if such a pandemic persists for an extended period of time, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which the Company is subject. Although the Company has been deemed essential and/or has been permitted to continue operating its facilities in the states in which it cultivates, processes, manufactures, and sells cannabis during the pendency of the COVID-19 pandemic, there is no assurance that the Company’s operations will continue to be deemed essential and/or will continue to be permitted to operate. The Company may incur expenses or delays relating to such events outside of its control, which could have a material adverse impact on its business, operating results, financial condition, and the trading price of the Common Shares.